English information

The Drug Information System of National Health Care Institute

Genees-en hulpmiddelen Informatie Project (GIP), Zorginstituut Nederland
The Netherlands

  • Objectives

    The GIP is an information system of National Health Care Institute, in use since 1988, containing information on expenditure on (extramural) drugs (= geneesmiddelen) in the Netherlands and the degree to which they are used. The register includes prescription-related data on drugs that are:

    • prescribed by general practitioners and specialists;
    • and dispensed by pharmacists, dispensing general practitioners and other outlets;
    • as well as being reimbursed under the Health Care Insurance Act.

    The information system also contains prescription-related data on medical aids under the Health Care Insurance Act (= hulpmiddelen):

    • prescribed by general practitioners and specialists;
    • dispensed by pharmacists, dispensing general practitioners and other outlets.

    To top

  • Register: input

    The GIP databases contain data from a representative sample of almost 16 million people (almost the whole Dutch population). The sample has been obtained from 10 health insurance organisations and has been extrapolated to the size of the entire Dutch population. For each prescription the following information is available:

    • patient-related: identification, gender, age and region;
    • drug-specific: name, dosage form, ATC-code, defined daily dose (DDD);
    • prescribers: general practitioners or type of specialists;
    • dispensers: pharmacists, dispensing general practitioners and other outlets;
    • prescription: date, dispensed amount and prescribed daily dose (PDD);
    • cost: pharmacy price, dispensing fee, VAT, reimbursement and personal contribution.

    To top

  • Output from GIPdatabank

    Output statistics are generated on all five ATC-levels. The following output statistics, which refer to the drug consumption of the total population, are provided by the GIPdatabank:

    • the total cost reimbursed;
    • the number of patients receiving at least one prescription;
    • the number of DDD's;
    • the number of prescriptions;

    As well as computed statistics such as:

    • total costs per patient receiving at least one prescription;
    • number of DDD's per patient;
    • total cost per DDD;
    • number of prescriptions per patient;
    • total costs per prescription;
    • number of DDD's per prescription.

    To top

  • How it works

    Since April 2005, consumer data at all ATC-levels have been publicly available on this website. Making a choice from “Geneesmiddelen” (drugs) takes you to consumer data with the ATC-classificy (2004) from the World Health Organization (WHO). If you know the ATC-code of the drug you are looking for, you can find it with ‘zoeken’.

    Making a choice from ‘Hulpmiddelen’ (medical technical aids for persons with disabilities) takes you to consumer data with the classificy of Index ISO9999: 2012. Afterwards you can chooce between different reports.

    If you want to see other key data, choose this in the last menu at the top.

    Totale kosten Total Cost excluding co-payment
    Gebruikers Users
    Uitgiftes Presciption
    DDD/uitgifte Total cost per User
    DDD/gebr DDD per User
    Tk/ddd Total cost per DDD
    Uitgiftes/gebr Prescriptions per user
    Tk/uitgifte total cost per prescription
    DDD/uitgifte DDD per prescription
    Totale kosten Total Cost excluding co-payment
    Gebruikers Users
    Declaraties Prescription
    Tk/gebr Total cost per User
    Tk/decl Prescriptions per user
    Decl/gebr total cost per prescription

    To top

  • Drug monitoring and publications

    The GIP information system is a powerful monitoring instrument for preparing and evaluating policy measures and forecasting costs and developments in consumption in the near future. It also can be used to estimate the extra costs of introducing new drugs into the reimbursement scheme, and to provide insurance organisations with detailed information about developments in the drug usage of their insured population in comparison with other organisations.

    Relevant publication: GIPeilingen, key statistics on drug consumption in the Netherlands

    To top

  • More information, Inquiries?

    National Health Care Institute
    GIP / Afdeling Verzekering Zakelijk
    P.O. Box 320
    1110 AH Diemen
    The Netherlands
    J.F. Piepenbrink MSc, advisor
    Telephone: +31 20 797.86.86
    E-mail: infogip@zinl.nl

    To top

  • National Health Care Institute (Zorginstituut Nederland)

    National Health Care Institute (Zorginstituut Nederland) co-ordinates the implementation and funding of the Health Insurance Act and the AWBZ (Exceptional Medical Expenses Act). Zorginstituut Nederland takes up an independent position: in between policy and practice; in between central government on the one hand and the health insurers, care-providers and citizens on the other.

    The tasks of Zorginstituut Nederland are laid down in statutes. The most well-known of these are:

    • Providing advice on the sum for contributions and the budgets for health insurers;
    • Managing contribution funds and distributing them over the health insurers;
    • Providing guidelines for carrying out new and existing legislation;
    • Monitoring adherence to the regulations of international conventions;
    • Informing health insurers, care-providers and citizens;
    • Monitoring the feasibility and efficiency of government plans;
    • Detecting and reporting bottlenecks in the practice of implementation.

    Zorginstituut Nederland comprises an executive board appointed by the Minister of Health, Welfare and Sport and a supportive organisation under the guidance of a management board. The executive board comprises seven independent executives.

    To top